Liquidia Corporation (LQDA)
- Previous Close
15.53 - Open
15.33 - Bid 15.29 x 100
- Ask 15.43 x 100
- Day's Range
14.97 - 15.84 - 52 Week Range
8.26 - 16.81 - Volume
1,246,496 - Avg. Volume
1,086,121 - Market Cap (intraday)
1.309B - Beta (5Y Monthly) 0.24
- PE Ratio (TTM)
-- - EPS (TTM)
-1.71 - Earnings Date Aug 5, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
27.00
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
www.liquidia.comRecent News: LQDA
View More
Performance Overview: LQDA
Trailing total returns as of 5/8/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LQDA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LQDA
View MoreValuation Measures
Market Cap
1.31B
Enterprise Value
1.29B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
88.07
Price/Book (mrq)
26.34
Enterprise Value/Revenue
91.01
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-43.49%
Return on Equity (ttm)
-209.35%
Revenue (ttm)
14M
Net Income Avi to Common (ttm)
-130.39M
Diluted EPS (ttm)
-1.71
Balance Sheet and Cash Flow
Total Cash (mrq)
176.48M
Total Debt/Equity (mrq)
158.38%
Levered Free Cash Flow (ttm)
-64.91M
Research Analysis: LQDA
View MoreResearch Reports: LQDA
View MoreDaily – Vickers Top Buyers & Sellers for 04/20/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 04/16/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/28/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/22/2021
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.